BioSpace News Archive

AcelRx Pharmaceuticals, Inc. today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences.

DiaMedica Therapeutics Inc. today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023.

Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced today that the first patient has been enrolled in its Phase 1b study combining temozolomide and eflornithine in patients newly diagnosed with glioblastoma.

ProMIS Neurosciences Inc. (Nasdaq: PMN) today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 4:30 p.m. ET in New York, NY.

Lisata Therapeutics, Inc. announced a positive outcome of the prespecified interim futility analysis for the ASCEND trial, a Phase 2b study evaluating LSTA1, Lisata’s lead investigational product, in combination with standard-of-care gemcitabine/nab-paclitaxel in patients with first-line, metastatic pancreatic ductal adenocarcinoma.

Terns Pharmaceuticals, Inc. announced that it has granted as of September 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences.

PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company) today announced that Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech, will participate and present an overview of the company and its programs at the H.C. Wainwright 25th Annual Global Investment Conference.

Organogenesis Holdings Inc. announced that company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 11th-13th.